2023
Long-term PCI outcomes in chronic versus acute coronary syndromes: 5-year results of the TARGET All Comers trial
Patel K, Lansky A, Kelbaek H, Xu B, Van Royen N, Johnson T, Anderson R, Wijns W, Baumbach A. Long-term PCI outcomes in chronic versus acute coronary syndromes: 5-year results of the TARGET All Comers trial. European Heart Journal 2023, 44: ehad655.1494. DOI: 10.1093/eurheartj/ehad655.1494.Peer-Reviewed Original ResearchAcute coronary syndromeChronic coronary syndromeProbable stent thrombosisCoronary syndromeStent thrombosisFIREHAWK stentLesion failureClinical presentationLong-term PCI outcomesPatient-oriented composite endpointTarget lesion revascularisationMajor adverse eventsLong-term outcomesLong-term safetyCCS cohortComer patientsID-TLRLesion revascularisationCCS patientsOpen labelAdverse eventsBaseline characteristicsACS cohortComposite endpointComers trial
2018
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial
Lansky A, Wijns W, Xu B, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Baumbach A, Investigators T. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. The Lancet 2018, 392: 1117-1126. PMID: 30190206, DOI: 10.1016/s0140-6736(18)31649-0.Peer-Reviewed Original ResearchConceptsLate lumen lossStent late lumen lossTarget lesion failureCoronary artery diseaseNon-inferiority trialXience groupPrimary endpointLesion failureLumen lossAbluminal grooveAngiographic substudyComers populationArtery diseaseMyocardial ischaemiaMyocardial infarctionIschaemia-driven target lesion revascularisationAsymptomatic coronary artery diseaseTarget vessel myocardial infarctionIschemic coronary artery diseaseST-elevation myocardial infarctionRandom block allocationTarget lesion revascularisationStent thrombosis ratesVessel myocardial infarctionElevation myocardial infarction
2014
First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients
Navarese EP, Kowalewski M, Kandzari D, Lansky A, Górny B, Kołtowski Ł, Waksman R, Berti S, Musumeci G, Limbruno U, van der Schaaf RJ, Kelm M, Kubica J, Suryapranata H. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart 2014, 1: e000064. PMID: 25332803, PMCID: PMC4189321, DOI: 10.1136/openhrt-2014-000064.Peer-Reviewed Original ResearchSecond-generation drug-eluting stentsPaclitaxel-eluting stentsDrug-eluting stentsSecond-generation EESCoronary artery diseaseMyocardial infarctionEnd pointArtery diseaseClinical trialsPrespecified safety end pointsStable coronary artery diseaseIncidence of MIFirst-generation drug-eluting stentsFirst-generation SESReduction of oddsEfficacy end pointSafety end pointTarget lesion revascularisationAcute coronary syndromeComposite end pointSafe drug-eluting stentCurrent clinical practiceLong-term safetyVessel revascularisationCardiac mortality
2013
Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study.
Buysschaert I, Dubois CL, Dens J, Ormiston J, Worthley S, McClean D, Ottervanger JP, Meredith I, Uren N, Wijns W, Whitbourn R, Mehran R, Lansky AJ, Bichalska M, Meis S, Verheye S. Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study. EuroIntervention 2013, 9: 573-81. PMID: 24058075, DOI: 10.4244/eijv9i5a93.Peer-Reviewed Original ResearchConceptsTarget lesion revascularisationIschaemia-driven target lesion revascularisationMajor adverse cardiac eventsSecondary safety endpointStent thrombosisMyocardial infarctionBifurcation lesionsAXXESS stentSafety endpointClinical outcomesBiolimus A9De novo coronary bifurcation lesionsThree-year clinical outcomesNew-generation drug-eluting stentsThree-year clinical resultsCumulative stent thrombosisProbable ST eventsAdverse cardiac eventsSingle-arm trialImproved clinical outcomesTrue bifurcation lesionsCoronary bifurcation lesionsDrug-eluting stentsPromising treatment strategyPresent large studyA randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL, Xu B, Lansky AJ, Yang YJ, Ma CS, Han YL, Chen SL, Li H, Zhang RY, Fu GS, Yuan ZY, Jiang H, Huo Y, Li W, Zhang YJ, Leon MB. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. EuroIntervention 2013, 9: 75-83. PMID: 23685298, DOI: 10.4244/eijv9i1a12.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedAnalysis of VarianceAntineoplastic AgentsChinaChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary StenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleHumansLeast-Squares AnalysisMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPolymersPredictive Value of TestsProspective StudiesProsthesis DesignSirolimusTime FactorsTreatment OutcomeConceptsIschaemia-driven target lesion revascularisationStent late lumen lossTarget vessel myocardial infarctionLate lumen lossTarget lesion failureSingle de novo coronary lesionsDe novo coronary lesionsNovo coronary lesionsCoronary lesionsPrimary endpointCardiac deathI trialNovel abluminal groove-filled biodegradable polymer sirolimus-eluting stentSingle de novo native coronary lesionsDe novo native coronary lesionsBiodegradable polymer sirolimus-eluting stentsNine monthsNative coronary lesionsProbable stent thrombosisTarget lesion revascularisationVessel myocardial infarctionSirolimus-eluting stentsNon-inferiority trialLesion revascularisationEES group
2002
Use of localised intracoronary β radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial
Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L, investigators I. Use of localised intracoronary β radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. The Lancet 2002, 359: 551-557. PMID: 11867107, DOI: 10.1016/s0140-6736(02)07741-3.Peer-Reviewed Original ResearchConceptsBinary angiographic restenosis ratePrimary safety endpointAngiographic restenosis rateTarget lesion revascularisationStent restenosisPlacebo groupSafety endpointRestenosis rateRadiated groupMyocardial infarctionMajor adverse cardiac eventsIntracoronary beta radiationIntracoronary β-radiationSuccessful coronary interventionAdverse cardiac eventsPrimary efficacy endpointRecurrence of restenosisBeta-radiation treatmentEfficacy endpointAngiographic outcomesCardiac eventsCoronary interventionIntracoronary stentingProcedural successVascular brachytherapy